-
1 Comment
Dynavax Technologies Corporation is currently in a long term uptrend where the price is trading 22.3% above its 200 day moving average.
From a valuation standpoint, the stock is 98.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 21.9.
Dynavax Technologies Corporation's total revenue rose by 85.0% to $20M since the same quarter in the previous year.
Its net income has increased by 57.9% to $-15M since the same quarter in the previous year.
Finally, its free cash flow grew by 33.5% to $-17M since the same quarter in the previous year.
Based on the above factors, Dynavax Technologies Corporation gets an overall score of 5/5.
| ISIN | US2681582019 |
|---|---|
| Industry | Drug Manufacturers-Specialty & Generic |
| Sector | Healthcare |
| CurrencyCode | EUR |
| Exchange | F |
| Dividend Yield | 0.0% |
|---|---|
| Target Price | 21.75 |
| PE Ratio | 4.9 |
| Market Cap | 1B |
| Beta | 1.45 |
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for DYF1.F using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2024
